Bibliography
- Mcintyre RS, Soczynska JK, Woldeyohannes HO, et al. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother 2007;8(7):1001-9
- Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 2004;1003(1-2):9-17
- Mcintyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):28-36
- Kemp DE, Gilmer WS, Fleck J, et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog. Neuropsychopharmacol. Biol Psychiatry 2007;31(2):574-7
- Sokolski KN. Adjunctive aripiprazole in bipolar I depression. Ann Pharmacother 2007;41(1):35-40
- Mcelroy SL, Suppes T, Frye MA, et al. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Aff Disord 2007;101(1-3):275-81
- Keck PE, Calabrese JR, Mcintyre RS, et al. The Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-91
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. American Psychiatric Association, Washington, DC:1994
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
- Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
- First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders – Patient Edition (SCID - I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute;1995
- Tohen M, Vieta E, Calabrese JR, et al. Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
- Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60
- Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in non-psychotic bipolar I depression. Results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28(1):13-20
- Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006;29:303-19